{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T04:21:50Z","timestamp":1667276510377},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10157-020-01906-8","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T08:03:51Z","timestamp":1593763431000},"page":"876-884","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influence of muscle mass on the estimation of glomerular filtration rate in Japanese terminal cancer patients"],"prefix":"10.1007","volume":"24","author":[{"given":"Yoshihiro","family":"Uekuzu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"1906_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.7326\/0003-4819-148-2-200801150-00009","volume":"148","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Shekelle P, Casey DE Jr, Cross JT Jr, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians, Dallas P, Dolan NC, Forciea MA, Halasyamani L, Hopkins RH Jr, Shekelle P. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:141\u20136.","journal-title":"Ann Intern Med."},{"key":"1906_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1248\/bpb.b16-00715","volume":"40","author":"Y Uekuzu","year":"2017","unstructured":"Uekuzu Y, Higashiguchi T, Futamura A, Ito A, Mori N, Murai M, Ohara H, Awa H, Chihara T. A clinical study on administration of opioid antagonists in terminal cancer patients: 7 patients receiving opioid antagonists following opioids among 2443 terminal cancer patients receiving opioids. Biol Pharm Bull. 2017;40:278\u201383.","journal-title":"Biol Pharm Bull"},{"key":"1906_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40262-015-0345-4","volume":"55","author":"LG Franken","year":"2016","unstructured":"Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, van Gelder T, Mathot RA. Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients. Clin Pharmacokinet. 2016;55:697\u2013709.","journal-title":"Clin Pharmacokinet"},{"key":"1906_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1089\/jpm.2011.0103","volume":"14","author":"G Paramanandam","year":"2011","unstructured":"Paramanandam G, Prommer E, Schwenke DC. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med. 2011;14:1029\u201333.","journal-title":"J Palliat Med"},{"issue":"280","key":"1906_CR5","first-page":"e1","volume":"120","author":"K Gooch","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(280):e1\u20137.","journal-title":"Am J Med"},{"key":"1906_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/bcp.13442","volume":"84","author":"LG Franken","year":"2018","unstructured":"Franken LG, de Winter BCM, Masman AD, van Dijk M, Baar FPM, Tibboel D, Koch BCP, van Gelder T, Mathot RAA. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2018;84:320\u201330.","journal-title":"Br J Clin Pharmacol"},{"key":"1906_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63:713\u201335.","journal-title":"Am J Kidney Dis"},{"key":"1906_CR8","volume-title":"Applied biopharmaceutics and pharmacokinetics","author":"S Leon","year":"2012","unstructured":"Leon S, Susanna WP, Andrew Y. Applied biopharmaceutics and pharmacokinetics. 6th ed. New York: McGraw-Hill Medical; 2012.","edition":"6"},{"key":"1906_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10157-008-0084-z","volume":"13","author":"M Horio","year":"2009","unstructured":"Horio M, Imai E, Yasuda Y, Hishida A, Matsuo S, Japanese Equation for Estimating GFR. Simple sampling strategy for measuring inulin renal clearance. Clin Exp Nephrol. 2009;13:50\u20134.","journal-title":"Clin Exp Nephrol."},{"key":"1906_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"1906_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.lfs.2018.04.013","volume":"202","author":"G Leto","year":"2018","unstructured":"Leto G, Crescimanno M, Flandina C. On the role of cystatin C in cancer progression. Life Sci. 2018;202:152\u201360.","journal-title":"Life Sci"},{"key":"1906_CR12","doi-asserted-by":"publisher","first-page":"c158","DOI":"10.1159\/000166607","volume":"110","author":"P Delanaye","year":"2008","unstructured":"Delanaye P, Cavalier E, Radermecker RP, Paquot N, Depas G, Chapelle JP, Scheen AJ, Krzesinski JM. Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa. Nephron Clin Pract. 2008;110:c158\u2013c163163.","journal-title":"Nephron Clin Pract"},{"key":"1906_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10157-015-1115-1","volume":"19","author":"K Shibata","year":"2015","unstructured":"Shibata K, Yasuda Y, Kobayashi R, Ando Y, Shimokata T, Kamiya H, Hayashi M, Maruyama S, Matsuo S, Nakao M, Tsuchiya T, Teramachi H. Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. Clin Exp Nephrol. 2015;19:1107\u201313.","journal-title":"Clin Exp Nephrol"},{"key":"1906_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10157-008-0043-8","volume":"12","author":"K Nakai","year":"2008","unstructured":"Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K, Suwabe A. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008;12:132\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1906_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00066-010-2203-5","volume":"187","author":"E B\u00f6lke","year":"2011","unstructured":"B\u00f6lke E, Schieren G, Gripp S, Steinbach G, Peiper M, Orth K, Matuschek C, Pelzer M, Lammering G, Houben R, Antke C, Rump LC, Mota R, Gerber PA, Schuler P, Hoffmann TK, Rusnak E, Hermsen D, Budach W. Cystatin C\u2014a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Strahlenther Onkol. 2011;187:191\u2013201.","journal-title":"Strahlenther Onkol"},{"key":"1906_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/ajco.12312","volume":"11","author":"JS Chew-Harris","year":"2015","unstructured":"Chew-Harris JS, Florkowski CM, George PM, Endre ZH. Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients. Asia Pac J Clin Oncol. 2015;11:142\u201351.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1906_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00280-017-3326-5","volume":"80","author":"M Bretagne","year":"2017","unstructured":"Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, Arrondeau J, Sarfati G, Goldwasser F, Alexandre J. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemother Pharmacol. 2017;80:45\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1906_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0022-5347(17)67149-0","volume":"114","author":"F Berglund","year":"1975","unstructured":"Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 1975;114:802\u20138.","journal-title":"J Urol"},{"key":"1906_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/bmj.2.6026.16","volume":"2","author":"HC Burry","year":"1976","unstructured":"Burry HC, Dieppe PA. Apparent reduction of endogenous creatinine clearance by salicylate treatment. Br Med J. 1976;2:16\u20137.","journal-title":"Br Med J"},{"key":"1906_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cca.2018.10.022","volume":"487","author":"Y Nozawa","year":"2018","unstructured":"Nozawa Y, Sato H, Wakamatsu A, Kobayashi D, Nakatsue T, Wada Y, Kuroda T, Kazama JJ, Suzuki Y, Nakano M, Narita I. Utility of estimated glomerular filtration rate using cystatin C and its interpretation in patients with rheumatoid arthritis under glucocorticoid therapy. Clin Chim Acta. 2018;487:299\u2013305.","journal-title":"Clin Chim Acta"},{"key":"1906_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0009-8981(00)00298-9","volume":"300","author":"N Cimerman","year":"2000","unstructured":"Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta. 2000;300:83\u201395.","journal-title":"Clin Chim Acta"},{"key":"1906_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1373\/49.4.680","volume":"49","author":"V Jayagopal","year":"2003","unstructured":"Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem. 2003;49:680\u20131.","journal-title":"Clin Chem"},{"key":"1906_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5414\/CN106792","volume":"76","author":"R Obrenovic","year":"2011","unstructured":"Obrenovic R, Petrovic D, Majkic-Singh N, Trbojevic-Stankovic J, Stojimirovic B. Serum cystatin C levels in normal pregnancy. Clin Nephrol. 2011;76:174\u20139.","journal-title":"Clin Nephrol"},{"key":"1906_CR24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/135965350801300810","volume":"13","author":"S Mauss","year":"2008","unstructured":"Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, Schauseil S, Schmutz G. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther. 2008;13:1091\u20135.","journal-title":"Antivir Ther"},{"key":"1906_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1258\/acb.2012.011241","volume":"50","author":"JS Chew-Harris","year":"2013","unstructured":"Chew-Harris JS, Florkowski CM, George PM, Elmslie JL, Endre ZH. The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Ann Clin Biochem. 2013;50:39\u201346.","journal-title":"Ann Clin Biochem"},{"key":"1906_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/0003-4819-113-7-501","volume":"113","author":"R Roubenoff","year":"1990","unstructured":"Roubenoff R, Drew H, Moyer M, Petri M, Whiting-O'Keefe Q, Hellmann DB. Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. Ann Intern Med. 1990;113:501\u20136.","journal-title":"Ann Intern Med"},{"key":"1906_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/jjco\/hyw105","volume":"46","author":"T Higashiguchi","year":"2016","unstructured":"Higashiguchi T, Ikegaki J, Sobue K, Tamura Y, Nakajima N, Futamura A, Miyashita M, Mori N, Inui A, Ohta K, Hosokawa T. Guidelines for parenteral fluid management for terminal cancer patients. Jpn J Clin Oncol. 2016;46:986\u201392.","journal-title":"Jpn J Clin Oncol"},{"key":"1906_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/014860717700100101","volume":"1","author":"GL Blackburn","year":"1977","unstructured":"Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr. 1977;1:11\u201322.","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"1906_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF02479909","volume":"1","author":"M Horio","year":"1997","unstructured":"Horio M, Orita Y, Manabe S, Sakata M, Fukunaga M. Formula and nomogram for predicting creatinine clearance from serum creatinine concentration. Clin Exp Nephrol. 1997;1:110\u20134.","journal-title":"Clin Exp Nephrol"},{"key":"1906_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis."},{"key":"1906_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/082585979601200102","volume":"12","author":"F Anderson","year":"1996","unstructured":"Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12:5\u201311.","journal-title":"J Palliat Care"},{"key":"1906_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2012.07.007","volume":"61","author":"M Horio","year":"2013","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S, Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197\u2013203.","journal-title":"Am J Kidney Dis."},{"key":"1906_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"1906_CR34","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303\u201311 (discussion 312\u20133).","journal-title":"Nutrition."},{"key":"1906_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503\u201312.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1906_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jjco\/hys235","volume":"43","author":"Y Funakoshi","year":"2013","unstructured":"Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Umezu M, Otsuki N, Nibu K, Minami H. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn J Clin Oncol. 2013;43:271\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1906_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10157-014-0988-8","volume":"19","author":"M Horio","year":"2015","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Yokoyama H, Makino H, Matsuo S. Serum albumin, but not glycated albumin was a potent factor affecting the performance of GFR equation based on serum creatinine. Clin Exp Nephrol. 2015;19:284\u201392.","journal-title":"Clin Exp Nephrol"},{"key":"1906_CR38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1592\/phco.31.4.346","volume":"31","author":"B Bhardwaja","year":"2011","unstructured":"Bhardwaja B, Carroll NM, Raebel MA, Chester EA, Korner EJ, Rocho BE, Brand DW, Magid DJ. Improving prescribing safety in patients with renal insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy (DRAP) program. Pharmacotherapy. 2011;31:346\u201356.","journal-title":"Pharmacotherapy"},{"key":"1906_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0065-2423(01)35015-1","volume":"35","author":"AO Grubb","year":"2000","unstructured":"Grubb AO. Cystatin C\u2014properties and use as diagnostic marker. Adv Clin Chem. 2000;35:63\u201399.","journal-title":"Adv Clin Chem"},{"key":"1906_CR40","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/j.1349-7006.2010.01729.x","volume":"101","author":"T Shimokata","year":"2010","unstructured":"Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 2010;101:2601\u20135.","journal-title":"Cancer Sci"},{"key":"1906_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u2013311.","journal-title":"Age Ageing."},{"key":"1906_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.atherosclerosis.2009.05.010","volume":"207","author":"LH Oterdoom","year":"2009","unstructured":"Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ. Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis. 2009;207:534\u201340.","journal-title":"Atherosclerosis"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-01906-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T23:05:09Z","timestamp":1667257509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-01906-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01906-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interests exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 128) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}